• LAST PRICE
    0.0290
  • TODAY'S CHANGE (%)
    Trending Down-0.0020 (-6.4516%)
  • Bid / Lots
    0.0290/ 290
  • Ask / Lots
    0.0320/ 443
  • Open / Previous Close
    0.0280 / 0.0310
  • Day Range
    Low 0.0280
    High 0.0305
  • 52 Week Range
    Low 0.0170
    High 0.0450
  • Volume
    6,566
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.031
TimeVolumeOTLC
09:32 ET30000.028
10:09 ET6660.029
10:40 ET20000.0305
11:57 ET4000.029
12:30 ET5000.029
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOTLC
Oncotelic Therapeutics Inc
12.6M
-2.5x
---
United StatesNKGN
NKGen Biotech Inc
12.6M
-0.1x
---
United StatesINTI
Inhibitor Therapeutics Inc
12.8M
-4.2x
---
United StatesHSTC
HST Global Inc
12.8M
-14.8x
---
United StatesPMCB
PharmaCyte Biotech Inc
13.1M
3.5x
---
United StatesSNSE
Sensei Biotherapeutics Inc
13.1M
-0.5x
---
As of 2024-11-25

Company Information

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

Contact Information

Headquarters
29397 Agoura Road Suite 107AGOURA HILLS, CA, United States 91301
Phone
650-635-7000
Fax
650-635-7001

Executives

Chairman of the Board, Chief Executive Officer
Vuong Trieu
Chief Financial Officer
Amit Shah
Chief Medical Officer - Translation Medicine, Director
Anthony Maida
Chief Medical Officer, Chief Regulatory Officer (Consultant)
Seymour Fein
Chief Business Officer
Saran Saund

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.6M
Revenue (TTM)
$0.00
Shares Outstanding
406.3M
Oncotelic Therapeutics Inc does not pay a dividend.
Beta
-0.26
EPS
$-0.01
Book Value
$0.03
P/E Ratio
-2.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.